IP Library Granted Patent US 12,458,680
Granted Patent B2
US 12,458,680 · App. 18/122,991 · Granted Nov 4, 2025

Reconstitutable teverelix-TFA composition

Inventors: Finn Larsen (Hawick, GB); Francois Boutignon (Clermont-Ferrand, FR); Guy Poland (Bristol, GB)
Assignee: Antev Limited
A61K38/09A61K9/0019A61K9/19A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,680
App. No.
18/122,991
Granted
Nov 4, 2025
Kind
B2
Abstract

The present invention relates to a reconstitutable teverelix-TFA composition having a predefined molar ratio of teverelix to trifluoroacetate which is below the molar ratio required for microcrystal formation. Said composition remains stable during storage e.g., at a temperature around 2-8° C. Upon reconstitution a fixed amount of trifluoroacetate can be added to said composition thereby effectively and simply achieving an exact and desired molar ratio in order to obtain a fluid, milky microcrystalline aqueous teverelix-TFA suspension.

Claims (12)

1 . A method of preparing a reconstitutable teverelix-trifluoroacetate (TFA) composition, wherein said method comprises

mixing teverelix and trifluoroacetate at a molar ratio of between 1:1.3 and 1:1.6, as determined by measuring a content of trifluoroacetate and teverelix in an aqueous teverelix-TFA solution using an HPLC method, thereby providing the aqueous teverelix-TFA solution without any microcrystals, and

drying the aqueous teverelix-TFA solution.

2 . The method according to claim 1 , wherein the aqueous teverelix-TFA solution is dried to an extent such that the provided reconstitutable teverelix-TFA composition comprises water in an amount of between 0.3% to 5% by weight based on the total weight of the reconstitutable teverelix-TFA composition.

3 . The method according to claim 1 , wherein said method comprises adjusting the molar ratio in the aqueous teverelix-TFA solution to a specific predefined molar ratio between 1:1.3 and 1:1.6 by adding trifluoroacetate to the aqueous teverelix-TFA solution before said aqueous teverelix-TFA solution is dried.

4 . The method according to claim 1 , wherein said method comprises drying the aqueous teverelix-TFA solution to a water content between 0.3% to 5% by weight based on the total weight of the reconstitutable teverelix-TFA composition.

5 . A reconstitutable teverelix-trifluoroacetate (TFA) composition having a molar ratio of teverelix (Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Hci-Leu-Lys (iPr)-Pro-D-Ala-NH 2 ) to trifluoroacetate between 1:1.3 and 1:1.6, as determined by measuring a content of trifluoroacetate and teverelix in an aqueous teverelix-TFA solution using an HPLC method, and wherein said composition does not comprise any microcrystals.

6 . The reconstitutable composition according to claim 5 , wherein water is present in the reconstitutable teverelix-TFA composition in an amount between 0.3% to 5% by weight based on the total weight of the reconstitutable teverelix-TFA composition.

7 . The reconstitutable composition according to claim 5 , wherein water is present in the reconstitutable teverelix-TFA composition in an amount between 1% by weight and 2% by weight.

8 . The reconstitutable composition according to claim 5 , wherein the reconstitutable composition is a powder or a cake.

9 . The reconstitutable composition according to claim 5 , wherein the reconstitutable composition is a powder obtained by lyophilization or spray-drying or a cake obtained by lyophilization.

10 . A package comprising a unit dosage of a reconstitutable teverelix-TFA composition having a molar ratio of teverelix (Ac-D-Nal-D-pClPhe-D-Pal-Ser-Tyr-D-Hci-Leu-Lys (iPr)-Pro-D-Ala-NH 2 ) to trifluoroacetate between 1:1.3 and 1:1.6, as determined by measuring a content of trifluoroacetate and teverelix in an aqueous teverelix-TFA solution using an HPLC method, and wherein said composition does not comprise any microcrystals.

Assignments (2)
SECURITY INTEREST Recorded Aug 17, 2026
From: ANTEV LIMITED
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 075671/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2025
From: LARSEN, FINN; BOUTIGNON, FRANCOIS; POLAND, GUY
To: ANTEV LIMITED
Reel/Frame 071680/0836 →
Priority Claims (1)
EP 18181931 · Jul 5, 2018 · regional
Continuity (2)
Continuation 17254859
Related Publication 20230285503A1 · Sep 14, 2023
References Cited (4)
US 20030044463A1 · Deghenghi et al. · 2003 [cited by applicant]
WO 2003022243 · 2003 [cited by applicant]
WO 2008071984 · 2008 [cited by applicant]
International Search Report and Written Opinion for International PCT Patent Application No. PCT/EP2019/067718, mailed Jul. 2, 2019 (10 pages). [cited by applicant]